非甾体抗炎药加重的呼吸道疾病的潜在生物标志物。
Potential Biomarkers for NSAID-Exacerbated Respiratory Disease.
机构信息
Department of Allergy and Clinical Immunology, Kyungpook National University School of Medicine, Daegu, Republic of Korea.
Department of Allergy and Clinical Immunology, Ajou University Medical Center, Suwon, Republic of Korea.
出版信息
Mediators Inflamm. 2017;2017:8160148. doi: 10.1155/2017/8160148. Epub 2017 Aug 9.
Abstract
Asthma is a common chronic disease with several variant phenotypes and endotypes. NSAID-exacerbated respiratory disease (NERD) is one such endotype characterized by asthma, chronic rhinosinusitis (CRS) with nasal polyps, and hypersensitivity to aspirin/cyclooxygenase-1 inhibitors. NERD is more associated with severe asthma than other asthma phenotypes. Regarding diagnosis, aspirin challenge tests via the oral or bronchial route are a standard diagnostic method; reliable diagnostic tests are not available. Recent studies have reported various biomarkers of phenotype, diagnosis, and prognosis. In this review, we summarized the known potential biomarkers of NERD that are distinct from those of aspirin-tolerant asthma. We also provided an overview of the different NERD subgroups.
摘要
哮喘是一种常见的慢性疾病，具有多种变异表型和内型。非甾体抗炎药加重的呼吸系统疾病（NERD）就是其中一种内型，其特征是哮喘、慢性鼻-鼻窦炎（CRS）伴鼻息肉和对阿司匹林/环氧化酶-1 抑制剂过敏。与其他哮喘表型相比，NERD 与严重哮喘的相关性更高。关于诊断，口服或支气管途径的阿司匹林激发试验是一种标准的诊断方法；目前还没有可靠的诊断测试。最近的研究报告了表型、诊断和预后的各种生物标志物。在这篇综述中，我们总结了与阿司匹林耐受型哮喘不同的 NERD 的已知潜在生物标志物。我们还概述了不同的 NERD 亚组。
相似文献
1
Potential Biomarkers for NSAID-Exacerbated Respiratory Disease.非甾体抗炎药加重的呼吸道疾病的潜在生物标志物。
Mediators Inflamm. 2017;2017:8160148. doi: 10.1155/2017/8160148. Epub 2017 Aug 9.
2
Nonsteroidal anti-inflammatory drug (NSAID) exacerbated respiratory disease phenotype: Topical NSAID and asthma control - A possible oversight link.非甾体抗炎药（NSAID）加重的呼吸道疾病表型：局部用NSAID与哮喘控制——一个可能被忽视的关联
Respir Med. 2016 Sep;118:1-3. doi: 10.1016/j.rmed.2016.07.004. Epub 2016 Jul 9.
3
From "Samter's Triad" to "NERD": The Long and Winding Road to Understanding Aspirin-Exacerbated Respiratory Disease.
Immunol Allergy Clin North Am. 2016 Nov;36(4):xiii-xiv. doi: 10.1016/j.iac.2016.08.002.
4
Nonsteroidal anti-inflammatory drugs-exacerbated respiratory disease in adolescents.青少年非甾体抗炎药加重的呼吸道疾病
Int Forum Allergy Rhinol. 2015 May;5(5):392-8. doi: 10.1002/alr.21494. Epub 2015 Mar 6.
5
Prostaglandin E decrease in induced sputum of hypersensitive asthmatics during oral challenge with aspirin.诱导痰中前列腺素 E 在口服阿司匹林激发的高敏哮喘患者中的下降。
Allergy. 2019 May;74(5):922-932. doi: 10.1111/all.13671. Epub 2018 Dec 5.
6
[The value of aspirin challenge tests in the diagnosis of non-steroidal anti-inflammatory drugs-exacerbated respiratory disease].[阿司匹林激发试验在非甾体类抗炎药加重的呼吸系统疾病诊断中的价值]
Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2023 Aug 7;58(8):741-746. doi: 10.3760/cma.j.cn115330-20230120-00035.
7
Nonsteroidal anti-inflammatory drug-exacerbated respiratory disease: diagnosis and current management.非甾体抗炎药加重的呼吸道疾病：诊断与当前管理。
Pol Arch Intern Med. 2023 Sep 29;133(9). doi: 10.20452/pamw.16544. Epub 2023 Aug 7.
8
Identification of phenotypic clusters of nonsteroidal anti-inflammatory drugs exacerbated respiratory disease.非甾体抗炎药加重呼吸道疾病表型簇的鉴定。
Allergy. 2017 Apr;72(4):616-626. doi: 10.1111/all.13075. Epub 2016 Dec 1.
9
Diagnostic Evaluation in Aspirin-Exacerbated Respiratory Disease.阿司匹林诱发的呼吸道疾病的诊断评估
Immunol Allergy Clin North Am. 2016 Nov;36(4):657-668. doi: 10.1016/j.iac.2016.06.003. Epub 2016 Sep 13.
10
Heterogeneity of NSAID-Exacerbated Respiratory Disease: has the time come for subphenotyping?非甾体抗炎药诱发的呼吸系统疾病的异质性：是否到了亚表型分型的时候？
Curr Opin Pulm Med. 2019 Jan;25(1):64-70. doi: 10.1097/MCP.0000000000000530.
引用本文的文献
1
[Expert consensus on the diagnosis and treatment of respiratory diseases exacerbated by nonsteroidal anti-inflammatory drugs （2024, Chengdu）].非甾体抗炎药诱发的呼吸系统疾病诊治专家共识（2024年，成都）
Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2024 Jun;38(6):453-462. doi: 10.13201/j.issn.2096-7993.2024.06.001.
2
New insights into the pathophysiology and therapeutic targets of asthma and comorbid chronic rhinosinusitis with or without nasal polyposis.哮喘和伴或不伴鼻息肉的慢性鼻-鼻窦炎的病理生理学和治疗靶点的新见解。
Clin Sci (Lond). 2023 May 18;137(9):727-753. doi: 10.1042/CS20190281.
3
Bacterial Extracellular Vesicles: A Candidate Molecule for the Diagnosis and Treatment of Allergic Diseases.细菌细胞外囊泡：过敏性疾病诊断与治疗的候选分子
Allergy Asthma Immunol Res. 2023 May;15(3):279-289. doi: 10.4168/aair.2023.15.3.279.
4
Immunologic Basis of Type 2 Biologics for Severe Asthma.重度哮喘2型生物制剂的免疫学基础
Immune Netw. 2022 Dec 5;22(6):e45. doi: 10.4110/in.2022.22.e45. eCollection 2022 Dec.
5
Immune Metabolism in TH2 Responses: New Opportunities to Improve Allergy Treatment - Disease-Specific Findings (Part 1).TH2 反应中的免疫代谢：改善过敏治疗的新机会——疾病特异性发现（第 1 部分）。
Curr Allergy Asthma Rep. 2023 Jan;23(1):29-40. doi: 10.1007/s11882-022-01057-8. Epub 2022 Nov 28.
6
Emerging Biomarkers Beyond Leukotrienes for the Management of Nonsteroidal Anti-inflammatory Drug (NSAID)-Exacerbated Respiratory Disease.白三烯之外用于非甾体抗炎药（NSAID）加重的呼吸道疾病管理的新兴生物标志物
Allergy Asthma Immunol Res. 2022 Mar;14(2):153-167. doi: 10.4168/aair.2022.14.2.153.
7
Potential Metabolic Biomarkers in Adult Asthmatics.成年哮喘患者潜在的代谢生物标志物
Metabolites. 2021 Jun 30;11(7):430. doi: 10.3390/metabo11070430.
8
Biomarkers for Severe Asthma: Lessons From Longitudinal Cohort Studies.重症哮喘的生物标志物：纵向队列研究的经验教训
Allergy Asthma Immunol Res. 2021 May;13(3):375-389. doi: 10.4168/aair.2021.13.3.375.
本文引用的文献
1
Exploration of the Sphingolipid Metabolite, Sphingosine-1-phosphate and Sphingosine, as Novel Biomarkers for Aspirin-exacerbated Respiratory Disease.探索鞘脂代谢物1-磷酸鞘氨醇和鞘氨醇作为阿司匹林加重性呼吸道疾病的新型生物标志物
Sci Rep. 2016 Nov 10;6:36599. doi: 10.1038/srep36599.
2
Identification of phenotypic clusters of nonsteroidal anti-inflammatory drugs exacerbated respiratory disease.非甾体抗炎药加重呼吸道疾病表型簇的鉴定。
Allergy. 2017 Apr;72(4):616-626. doi: 10.1111/all.13075. Epub 2016 Dec 1.
3
Lipid Mediators in Aspirin-Exacerbated Respiratory Disease.阿司匹林加重性呼吸疾病中的脂质介质
Immunol Allergy Clin North Am. 2016 Nov;36(4):749-763. doi: 10.1016/j.iac.2016.06.009.
4
Aspirin-Exacerbated Respiratory Disease as an Endotype of Chronic Rhinosinusitis.阿司匹林加重性呼吸疾病作为慢性鼻-鼻窦炎的一种内型
Immunol Allergy Clin North Am. 2016 Nov;36(4):669-680. doi: 10.1016/j.iac.2016.06.004. Epub 2016 Sep 13.
5
Aspirin-exacerbated respiratory disease: an update.阿司匹林加重性呼吸疾病：最新进展
Curr Opin Pulm Med. 2017 Jan;23(1):89-96. doi: 10.1097/MCP.0000000000000328.
6
Using Periostin as a Biomarker in the Treatment of Asthma.将骨膜蛋白用作哮喘治疗的生物标志物。
Allergy Asthma Immunol Res. 2016 Nov;8(6):491-8. doi: 10.4168/aair.2016.8.6.491.
7
Eicosanoid Mediators in the Airway Inflammation of Asthmatic Patients: What is New?哮喘患者气道炎症中的类二十烷酸介质：有哪些新进展？
Allergy Asthma Immunol Res. 2016 Nov;8(6):481-90. doi: 10.4168/aair.2016.8.6.481.
8
Metabolomic analysis identifies potential diagnostic biomarkers for aspirin-exacerbated respiratory disease.代谢组学分析确定了阿司匹林诱发的呼吸道疾病的潜在诊断生物标志物。
Clin Exp Allergy. 2017 Jan;47(1):37-47. doi: 10.1111/cea.12797. Epub 2016 Sep 27.
9
Aspirin or Nonsteroidal Anti-inflammatory Drug-Exacerbated Chronic Rhinosinusitis.阿司匹林或非甾体抗炎药诱发的慢性鼻-鼻窦炎
J Allergy Clin Immunol Pract. 2016 Jul-Aug;4(4):590-8. doi: 10.1016/j.jaip.2016.04.011.
10
Update on the Management of Aspirin-Exacerbated Respiratory Disease.阿司匹林诱发的呼吸道疾病管理的最新进展
Allergy Asthma Immunol Res. 2016 Jul;8(4):298-304. doi: 10.4168/aair.2016.8.4.298.
Zotero 插件